MODULE 2
HOW TO EDUCATE PARENTS ON CRADLE WITH CARE℠ AND ACCESS 360™

Coordinator Corner has developed this summary to assist your learning and help you fully understand the information featured in this video

Video breakdown by topic

1 Topic: Importance of parents enrolling in Cradle with Care and Access 360 | Time: 0:21

• Enrolling in Cradle with Care: Parents have the option to enroll on their own—either by going online at CradleWithCare.com or by using the business reply card in the patient brochure

• Transition of Care (TOC) form: The TOC form is usually filled out prior to a high-risk baby’s discharge from the hospital
  – When you receive the TOC form from the hospital:
    · Check to see if the patient already opted in to one or both of the support programs
    · If they have, make a note of it in the patient ID log
  – Patient Authorization Form (PAF): Use the PAF if parents haven’t opted in to the programs
    · Allows MedImmune to help with access issues
    · Is available in print and electronic forms
    · Completing the online PAF at synagisPAF.com can help avoid issues of missing information or illegible handwriting

All Cradle with Care enrollment materials and communications are available in English and Spanish.

• Coordinator quick tips
  – Some parents may want to opt in to these programs immediately
    · Have them complete and sign the PAF in your office
  – Some parents may feel overwhelmed and need your understanding
    · Give these parents a PAF that is already filled out to take home and sign, along with a self-addressed envelope. This makes it easy for them to consider the programs once they are settled at home
    · Note: Please submit their PAF before RSV season starts

INDICATION
SYNAGIS® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:
• with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
• with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
• with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

Please see additional Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.
**Topic: Talking to parents about the Cradle with Care program** | **Time: 2:22**

- **Introducing program:** Parents may not understand that the effort of signing up is worth what they may get out of it. Clearly communicate the program’s benefits and help them understand how Cradle with Care can meet their needs
  - Comprehensive Patient Brochure: Use this as a visual aid for patient discussions, pointing out key information that may be relevant to their baby, or give it to them to read on their own time. It is also available in Spanish for Spanish-speaking parents and caregivers

- **Sharing the benefits of the program:** Helpful quick tip for starting the conversation
  - Explain to the parent: “It is important to stay on top of monthly dosing and Cradle with Care is designed to help you with that”

- **Explaining the benefits of the program:** Reminders
  - Parents can receive these reminders via email, text, or mail. Text messaging is often the preferred and most efficient way to deliver these reminders. If parent is interested in receiving text message reminders, record his or her mobile number on the enrollment form
    - Seasonal reminders: Cradle with Care reminders are sent at the start and end of RSV season in the patient’s area. Parents can focus prevention efforts during those peak months
    - Appointment reminders: Sent to parents in advance of every SYNAGIS® (palivizumab) appointment, so their baby never misses a dose of SYNAGIS
    - Second-season reminders: Certain high-risk babies may need therapy with SYNAGIS through his or her second RSV season, these reminders automatically extend through the second season as well, where allowed

- **Explaining the benefits of the program:** Education
  - Cradle with Care can also educate parents about populations at high risk for severe RSV disease and provide them with RSV protection tips

- **Explaining the benefits of the program:** Support
  - After they enroll, parents receive a welcome email or letter as well as a helpful Welcome Kit that includes:
    - An information booklet on RSV, SYNAGIS, and Cradle with Care
    - Hand sanitizer
    - Stroller tag (reminds people to wash their hands before touching the baby)
    - Special calendar (keeps track of important dates and milestones)

**IMPORTANT SAFETY INFORMATION**

- SYNAGIS is contraindicated in children who have had a previous significant hypersensitivity reaction to SYNAGIS.

Please see additional Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.
3 **Topic: Talking to parents about Access 360** | **Time: 6:06**
- Access 360 is a free program and can help patients:
  - Understand their coverage for MedImmune products and their financial obligation
  - Connect with resources to cover the cost of their prescribed MedImmune products
- Access 360 programs: Every family is different with different affordability situations, and Access 360 can connect parents with several different programs that are right for them
  - SYNAGIS® (palivizumab) Patient Savings Program: This program assists eligible commercially insured patients who have private insurance with out-of-pocket costs for SYNAGIS
    - The specialty pharmacy, home care company, prescriber’s office, or Access 360 can help them enroll in the program
  - Referral to foundation: Patient assistance is available through an Independent Non-profit Organization (INO)
    - If eligible, patients could receive a grant that helps cover out-of-pocket costs for SYNAGIS
    - Access 360 can refer parents to an independent foundation and their doctor or specialty pharmacy can help them complete the application for support
  - AZ&Me Prescription Savings Program: Remind parents to contact Access 360 to learn about this program

4 **Topic: Your role in helping parents prepare for the unexpected** | **Time: 7:44**
- Covering copays for SYNAGIS: Parents should always be able to contact you with any questions they may have about switching jobs, changing their insurance, or determining their deductible limit
- Affordability concerns can add to the stress of caring for a high-risk baby. You can play a huge role in building hope and confidence, simply by helping parents understand their options in accessing therapy with SYNAGIS

5 **Topic: Resources to help with your discussions with parents** | **Time: 8:31**
- You can also find information about affordability assistance programs in the Resources section of this module
- To help you discuss Cradle with Care and Access 360, we’ve also included a summary of key discussion points in the Resources section
  - Use it to make sure you cover these essential topics with parents and caregivers

If you want to become an official certified SYNAGIS coordinator, Coordinator Corner will help you every step of the way. All you have to do is view all the modules and take all the checkpoints to become certified and eligible to receive an educational textbook, or you can make a charitable donation.

You must be registered to be eligible for certification—so register today.

**IMPORTANT SAFETY INFORMATION**

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see additional Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.
IMPORTANT SAFETY INFORMATION (continued)

• SYNAGIS is contraindicated in children who have had a previous significant hypersensitivity reaction to SYNAGIS.
• Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to SYNAGIS. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to SYNAGIS. The relationship between these reactions and the development of antibodies to SYNAGIS is unknown. If a significant hypersensitivity reaction occurs with SYNAGIS, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of SYNAGIS.
• As with any intramuscular injection, SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder.
• Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.
• Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

INDICATION

SYNAGIS is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:
• with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
• with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
• with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

DOSEDING

The recommended dose of SYNAGIS is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of SYNAGIS should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of SYNAGIS at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Please see accompanying full Prescribing Information for SYNAGIS, including Patient Information.